SCHEMBL20138241

SCHEMBL20138241

Cc1nc2ccccn2c1CN1C(=O)[C@@H](C)Oc2ccc(-c3cccc(S(N)(=O)=O)c3)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.39
HSD17B10 Q99714 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CDK4 P11802 1/20 0.33
CDK2 P24941 1/20 0.33
CA2 P00918 5/20 0.33
CA9 Q16790 5/20 0.33
CA4 P22748 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SLC2A1 P11166 1/20 0.32
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20137911 0.93 MTOR (0.38) MTORHSD17B10NPSR1LMNAGAA
SCHEMBL20138243 0.86 MTOR (0.38) MTORLMNAGAASMN1; SMN2L3MBTL1
SCHEMBL20138229 0.86 MTOR (0.38) MTORLMNAGAASMN1; SMN2L3MBTL1
SCHEMBL20138144 0.80 MTOR (0.41) MTORHSD17B10NPSR1ALDH1A1TSHR
SCHEMBL20138088 0.79 MTOR (0.31) MTOR
SCHEMBL20138255 0.79 MAPK1 (0.36) MTORSLC2A1
SCHEMBL20138214 0.78 TSHR (0.35) NPSR1GAAMEN1KMT2AKDM4E
SCHEMBL20138179 0.78 TSHR (0.35) NPSR1GAAMEN1KMT2AKDM4E
SCHEMBL20138043 0.72 MEN1 (0.34) HSD17B10NPSR1LMNAGAAHPGD
SCHEMBL20138190 0.72 SMN1; SMN2 (0.38) MTORNPSR1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A MTOR 3479/4885HSD17B10 1111/4885NPSR1 1482/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA MTOR 3921/4885HSD17B10 2471/4885NPSR1 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.